Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Ablynx to Present Rheumatoid Arthritis Data at 2012 American College of Rheumatology Annual Meeting

GHENT, BELGIUM -- (Marketwire) -- 11/09/12 -- Ablynx (EURONEXT BRUSSELS: ABLX) today announced that it will present data from two Nanobody®-based products in rheumatoid arthritis (RA) at the annual meeting of the American College of Rheumatology (ACR) from 10-14 November in Washington D.C., USA. The poster presentations will be based on the outcome of pre-clinical and clinical studies that have previously been disclosed.

Ablynx will have three poster sessions including two posters on its novel IL-6R Nanobody, ALX-0061, and one poster on its novel anti-TNFa Nanobody, ozoralizumab (ATN-103).

ALX-0061 is a bi-specific IL-6R targeting Nanobody with monovalent binding to IL-6R and human serum albumin. Translational modelling studies resulted in a novel first-in-human design that combined a single-ascending dose, a multiple ascending dose and clinical POC using pharmacokinetics, biomarker and early clinical read outs as decision tools. Earlier reported results from the 12 week interim analysis of the Phase I/II study demonstrate that ALX-0061 has the potential to become a best-in-class IL-6R inhibitor in RA with a strong efficacy profile based on a 80% ACR20 response, a 60% DAS28-CRP remission rate, and a fast onset of DAS28-CRP remission; and an excellent safety profile with no serious infections, no decrease in neutrophils, no clinically significant increases in liver enzymes and no increases in lipid levels (cholesterol and LDL) being observed.

Ozoralizumab, ATN-103, a novel TNFa inhibitor, is a trivalent, bi-specific Nanobody that potently neutralises TNF and binds to human serum albumin to increase its in vivo half-life. The results from the Phase II open-label extension study demonstrated that ozoralizumab enables highly effective and well-tolerated individualised treatment. The specific molecular features of Nanobodies, including their small size, low immunogenic potential and manufacturability, contributed to the desired outcome, with the majority of patients showing marked improvement in their disease activity. Moreover, the once-induced remission could be maintained at doses less than 80mg monthly. This treatment approach could be beneficial to patients and minimise treatment costs.

Details on the poster sessions
Abstract/poster #336:
Pre-clinical development of ALX-0061, an anti-IL-6R Nanobody for therapeutic use in rheumatoid arthritis with a high in vitro affinity and potency and a competitive in vivo pharmacological profile - 11 November
Abstract/poster #1307: Anti-IL-6 receptor Nanobody (ALX-0061) seamless "first-in-human" Phase I/II POC study in patients with active RA on stable MTX treatment- 12 November
Abstract/poster #1311: A novel individualised treatment approach in open-label extension study of ozoralizumab (ATN-103) in subjects with rheumatoid arthritis on a background of methotrexate - 12 November

About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

press release in pdf: http://hugin.info/137912/R/1656461/535559.pdf

For more information, please contact
Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e: ablynx@mcomgroup.com

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
Many workloads are already in the cloud: Most organizations today run at least some workloads in the cloud. For newer organizations, they will often run ALL of their workloads in the cloud. For cloud-based workloads, sending log data to a cloud-based logging provider is not quite as bi...
As this year comes to a close, let's take one last look at the most pervasive cloud computing trends -- including increased usage across the different cloud service models, the key business drivers and the impact of agile innovation strategies.

Cloud computing adoption has m...
Many projected use cases for IoT won’t directly generate revenues. To achieve greater efficiency, companies are deploying IoT sensors internally throughout their organizations to optimize their use of everything from computer servers to lighting to HVAC systems to employee productivity...
Cloud computing seems to still be one of the reigning buzzwords in high-tech these days. Everything is either “in the cloud”, “powered by the cloud”, or some variation on the theme. I remember when hosted email was just that: hosted email. Today, such offerings are considered cloud off...
The book The Cyber Threat was written to provide business and government executives insight into the nature of the dynamic adversaries attacking our networks. Understanding the Cyber Threat is critical to preparing your defenses prior to attack and also instrumental in mounting a de...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE